Show simple item record

dc.contributor.advisorErnst R. Berndt and Charles L. Cooney.en_US
dc.contributor.authorThedinga, Angela (Angela Marie)en_US
dc.contributor.otherLeaders for Global Operations Program.en_US
dc.date.accessioned2010-10-12T18:10:39Z
dc.date.available2010-10-12T18:10:39Z
dc.date.issued2010en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/59187
dc.descriptionThesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering; in conjunction with the Leaders for Manufacturing Program at MIT, 2010.en_US
dc.description"June 2010." Cataloged from PDF version of thesis.en_US
dc.descriptionIncludes bibliographical references (p. 64).en_US
dc.description.abstractThis thesis investigates the use of a task-based Monte Carlo simulation model to forecast headcount and manufacturing capacity requirements for a drug development organization. A pharmaceutical drug development group is responsible for designing the manufacturing process for new potential drug products, testing the product quality, and supplying product for clinical trials. The drug development process is complex and uncertain. The speed to market is critical to a company's success. Therefore, it is important to have an adequate number of employees and available manufacturing capacity to support timely and efficient drug development. The employees and manufacturing capacity can either be supplied internally or externally, through contract manufacturing organizations. This thesis formulates and empirically evaluates a simulation model designed using the Novartis Biologics drug development process and is adaptable to other pharmaceutical organization. The model demonstrates 7% accuracy when compared with historical data, and estimates within 13% of the currently accepted manufacturing capacity forecasting tool. Additionally, three case studies are included to demonstrate how the model can be used to evaluate strategic decisions. The case studies include: a drug development process improvement evaluation, an outsourcing evaluation, and an "at risk" development evaluation.en_US
dc.description.statementofresponsibilityby Angela Thedinga.en_US
dc.format.extent70 p.en_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsM.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectSloan School of Management.en_US
dc.subjectChemical Engineering.en_US
dc.subjectLeaders for Global Operations Program.en_US
dc.titleForecasting resource requirements for drug development long range planningen_US
dc.typeThesisen_US
dc.description.degreeS.M.en_US
dc.description.degreeM.B.A.en_US
dc.contributor.departmentLeaders for Global Operations Program at MITen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Chemical Engineering
dc.contributor.departmentSloan School of Management
dc.identifier.oclc659832484en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record